Innate, T-, and B-Cell Responses in Acute Human Zika Patients

Lilin Lai, Emory University
Nadine Rouphael, Emory University
Yongxian Xu, Emory University
Muktha Natrajan, Emory University
Allison Beck, Emory University
Mari Hart, Emory University
Matthew Feldhammer, Emory University
Amanda Feldpausch, Georgia Department of Public Health
Charles Hill, Emory University
Henry Wu, Emory University

Only first 10 authors above; see publication for full author list.

Journal Title: Clinical Infectious Diseases
Volume: Volume 66, Number 1
Publisher: Oxford University Press (OUP): Policy B - Oxford Open Option C | 2018-01-01, Pages 1-+
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1093/cid/cix732
Permanent URL: https://pid.emory.edu/ark:/25593/s8qx7

Final published version: http://dx.doi.org/10.1093/cid/cix732

Copyright information:
© The Author(s) 2017.
This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).

Accessed May 26, 2018 2:26 PM EDT
Innate, T-, and B-Cell Responses in Acute Human Zika Patients


Background. There is an urgent need for studies of viral persistence and immunity during human Zika infections to inform planning and conduct of vaccine clinical trials. 

Methods. In 5 returned US travelers with acute symptomatic Zika infection, clinical features, viral RNA levels, and immune responses were characterized.

Results. Two pregnant, flavivirus-experienced patients had viral RNA persist in plasma for >44 and >26 days. Three days after symptom onset, transient increases in proinflammatory monocytes began followed at 5 days by transient decreases in myeloid dendritic cells. Anti-Zika virus immunoglobulin M was detected at day 7 after symptom onset, persisted beyond 103 days, and remained equivocal through day 172. Zika virus–specific plasmablasts and neutralizing antibodies developed quickly; dengue virus–specific plasmablasts and neutralizing antibodies at high titer developed only in flavivirus-experienced patients. Zika virus– and dengue virus–specific memory B cells developed in both flavivirus-naïve and -experienced patients. CD4+ T cells were moderately activated and produced antiviral cytokines after stimulation with Zika virus C, prM, E, and NS5 peptides in 4/4 patients. In contrast, CD8+ T cells were massively activated, but virus-specific cells that produced cytokines were present in only 2/4 patients assessed.

Conclusions. Acute infections with Zika virus modulated antigen-presenting cell populations early. Flavivirus-experienced patients quickly recalled cross-reactive MBCs to secrete antibodies. Dengue virus–naïve patients made little dengue-specific antibody but developed MBCs that cross-reacted against dengue virus. Zika virus–specific functional CD4+ T cells were readily detected, but few CD8+ T cells specific for the tested peptides were found.

Keywords. Zika; immunity; pregnancy; viral persistence; flavivirus.

Each year hundreds of thousands of US travelers return from countries where the Zika virus (ZIKV) epidemic has occurred. As of 19 July 2017, 5120 US travelers had been diagnosed with Zika [1]. ZIKV infections in pregnant women may produce the congenital Zika syndrome in fetuses [2–4]. ZIKV infections in adults are linked to rare, serious neurologic complications including Guillain-Barré syndrome [5–7]. Cardiac complications were recently reported [8, 9]. Studies of human ZIKV infections (including flavivirus-experienced or –naive hosts and pregnant women) are needed to optimally inform testing of Zika vaccines [10–14]. Immune responses to ZIKV infection were evaluated in a macaque model [15], but there are remarkably few published human studies of fundamental parameters such as the magnitude, kinetics, quality, and specificity of innate, effector, and memory cellular responses to ZIKV [16–18]. Dengue virus (DENV) immunity may be a useful point of reference; however, ZIKV has only a single serotype [16], which is an advantage for ZIKV vaccine development and testing. Human studies of DENV have identified early host responses such as loss of myeloid dendritic cells (DC) and increases in CD14+CD16+ monocytes, followed by robust expansions of plasmablasts [19]. After yellow fever (YF)-17D immunization, an increase in CD38+HLA-DR+ activated CD8+ T cells was detected in all vaccine recipients and was associated with transient plasma viral RNA detection. The peak of the CD8+ T-cell response was observed at day 15 after immunization, when 4%-13% of CD8+ T cells coexpressed CD38 and HLA-DR [20].

Here, we present immune response and viral persistence data from 5 acute ZIKV infections.
METHODS

Patients with confirmed ZIKV infections were identified and offered participation in an Emory University Institutional Review Board–approved protocol to study emerging infections. Time points in this convenience sample were designated as the days post onset of symptoms (DPO).

Quantitative real-time polymerase chain reaction (qRT-PCR) for Zika diagnosis or ZIKV persistence was performed on multiple body fluids as described [21]. For patient D, sera rather than plasma were assayed [22]; for simplicity the word plasma is used.

The contemporary ZIKV strain used for focus reduction neutralization test (FRNT) and Zika IgM antibody capture enzyme-linked immunosorbent assay (Zika MAC-ELISA) (PRVABC59 [KU501215.1]) was provided by the US Centers for Disease Control and Prevention. DENV-1 (Hawaii), DENV-2 (New Guinea C), and DENV-4 (H241) viruses were provided by BEI Resources (https://www.beiresources.org). DENV-3 (Slaman/78) was provided by Jens Wrammert (Emory University). ZIKV was passaged by infecting Vero cells (American Type Culture Collection; CRL-1586) at a multiplicity of infection of 0.05 in serum-free minimum essential medium (MEM; Life Technologies Gibco). After a 1-hour infection at 37°C, MEM supplemented with 10% (vol/vol) fetal bovine serum (FBS) and 1% antibiotic/antimycotic (Corning) were added. Upon observation of severe cytopathic effect at day 3, supernatants were collected and spun down at 930 x g for 10 minutes at 4°C. Virus-containing supernatant was supplemented with an additional 10% (vol/vol) FBS before freezing at –80°C. DENV-1–4 viruses were also passaged as described above, and virus-containing supernatants were collected at 8–11 days post-infection. Titers of the passaged viruses were determined by focus forming assay [23]. For the IgM antibody-capture enzyme-linked immunosorbent assay (MAC-ELISA) immunoglobulin (Ig) M assay [24], viral stocks were inactivated with 0.1% beta-propiolactone over night. Antigen was produced by spinning inactivated supernatants in Amicon Ultra-15 centrifugal filters at 3500 g for 10 minutes at 4°C. Virus-containing supernatant was supplemented with an additional 10% (vol/vol) FBS before freezing at –80°C. DENV-1–4 viruses were also passaged as described above, and virus-containing supernatants were collected at 8–11 days post-infection. Titers of the passaged viruses were determined by focus forming assay [23]. For the IgM antibody-capture enzyme-linked immunosorbent assay (MAC-ELISA) immunoglobulin (Ig) M assay [24], viral stocks were inactivated with 0.1% beta-propiolactone over night. Antigen was produced by spinning inactivated supernatants in Amicon Ultra-15 centrifugal filters at 3500 x g for 25 minutes at 4°C.

ZIKV lysate for B cell enzyme-linked immunospot (ELISpot) assays was prepared from Vero cells infected as above. After cell-free virus was harvested, the remaining adherent cells and cell pellet from the supernatant were washed twice with phosphate-buffered solution and resuspended in radioimmunoprecipitation assay (RIPA) buffer (Abcam; Ab156034) supplemented with protease inhibitor (Thermo Fisher Scientific; 87785) and phosphatase inhibitor (Biovision; K275-1). Mock lysate was prepared similarly from uninfected cells. Protein concentrations were quantified using NanoDrop 8000 (ThermoFisher). DENV-1–4 recombinant E proteins were purchased from CTK Diagnostics (A2301, DENV-1 VN/BID-V949/2007; A2302, DENV-2 GWL39 IND-01; A2303, DENV-3 US/BID-V1090/1998; and A2304, DENV-4 341750).

Peptide pools for intracellular cytokine staining (ICS) assays consisted of 15-mers with 11 amino acid overlaps spanning ZIKV proteins C (28 peptides), prM (40 peptides), and E (pool 1, 62 peptides; pool 2, 62 peptides) [JPT Peptide Technologies, Berlin, Germany; GenBank: KU527068]. Pools of 10 overlapping 15-mer peptides derived from ZIKV NS5 (GenBank: KU321639.1) were provided by D. H. O’Connor (University of Wisconsin–Madison) and synthesized using GenScript (Piscataway, New Jersey) [15].

Further experimental methods for immune phenotyping of innate cells by flow cytometry, focus reduction neutralization test (FRNT), MAC-ELISA, West Nile virus (WNV) ELISA, B-cell ELISpot, and intracellular cytokine staining (ICS) are provided in the Supplementary Materials.

RESULTS

Five returned travelers with acute Zika confirmed by qRT-PCR were enrolled between DPOs 3 and 11 and followed for up to 11 months (Table 1). Clinical signs and symptoms included rash (5/5), myalgia (4/5), fever (4/5), prolonged fatigue (4/5), joint pain (2/5), and conjunctivitis (1/5); most resolved in 1–3 weeks (Table 2).

Patient A-23. A 27-year-old healthy male who was flavivirus naive and had vacationed in Belize (Table 1). Upon return to the United States, his acute illness began (Table 2). He was leukopenic on DPO 3 with gradual resolution. ZIKV RNA was present in plasma on DPOs 3 and 5 (with the detected peak on DPO 3); in semen on DPO 9 (the only day assessed); in urine through DPO 18; and in whole blood through DPO 30 (Figure 1A and B). Fatigue persisted for 1 month.

CD14+/CD16+ proinflammatory monocytes were increased and at their detected peak on DPO 5 (when first assessed) and decreased to a presumed baseline by DPO 18 (Figure 1C). Myeloid dendritic cells (mDCs) decreased to a nadir on DPO 9 and increased to a presumed baseline by DPO 30 (Figure 1D). Anti-ZIKV IgM was not detected on DPO 5, was positive on DPOs 9 through 30, decreased to equivocal on DPO 60, and was absent on DPO 235 (Figure 2A, Table 1). Neutralizing antibodies (NAb) against ZIKV was first detected on DPO 9, peaked on DPO 18 (at a titer of 3278) when viral RNA in urine and whole blood were present but decreasing, and by DPO 235 had decreased only 3.3-fold (to 985; Figure 2A, Table 1). NAb against DENV-1–4 and ELISA Ab against WNV were negative in this naive patient (Figure 2B, Table 1). On DPOs 5–18 a striking rise and fall of phenotypic antibody-secreting cells (ASCs) occurred, peaking at 31% of all blood B lymphocytes (Figure 1E). The ASCs’ specificity for ZIKV was demonstrated by ELISpot assay, and there were no anti-DENV-1–4–, WNV–, or yellow fever virus (YFV)-specific ASCs (flavivirus-naive
Table 1. Demographics, Characteristics, and Antibody Responses for 5 Acute Zika Patients: Categorization as Flavivirus Experienced or Flavivirus Naive

<table>
<thead>
<tr>
<th>Patient (age, gender, country visited, reason)</th>
<th>Reported Previous Flavivirus Exposure; DPO when ZIKV PCR Diagnosis Made</th>
<th>Flavivirus Exposure Category (Pregnancy Status)</th>
<th>IgM (MAC-ELISA)*</th>
<th>Neutralizing Ab to ZIKV and DENVs (FRNT_{50} titer)</th>
<th>IgG (ELISA titer)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A-23 (27, male, Belize, vacation)</td>
<td>None; 3 Naive (NA)</td>
<td>DPO</td>
<td>ZIKV</td>
<td>ZIKV DENV-1 DENV-2 DENV-3 DENV-4 WNV</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5 0.7 &lt;30 &lt;30 &lt;30 &lt;30 &lt;30 &lt;30 &lt;30 ND &lt;10 10&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>9 4.3 415 &lt;30 &lt;30 &lt;30 &lt;30 &lt;30 &lt;30 ND &lt;10 10&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>18 8.1 3278 &lt;30 &lt;30 &lt;30 &lt;30 &lt;30 &lt;30 ND &lt;10 10&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>30 5.4 2654 &lt;30 &lt;30 &lt;30 &lt;30 &lt;30 &lt;30 ND &lt;10 10&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>60 2.9 1287 &lt;30 &lt;30 &lt;30 &lt;30 &lt;30 &lt;30 ND &lt;10 10&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>235 1.0 985 &lt;30 &lt;30 &lt;30 &lt;30 &lt;30 &lt;30 ND &lt;10 10&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B-17 (26, F, Honduras, mission work)</td>
<td>None; 1 Naive (not pregnant)</td>
<td>DPO</td>
<td>ZIKV</td>
<td>ZIKV DENV-1 DENV-2 DENV-3 DENV-4 WNV</td>
<td></td>
</tr>
<tr>
<td></td>
<td>7 4.8 1438 &lt;30 &lt;30 &lt;30 &lt;30 &lt;30 &lt;30 ND &lt;10 10&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-16 (32, F, Honduras, mission work)</td>
<td>Missionary in Honduras since 2010 and YF-17D vaccine in 2010; 3</td>
<td>Experienced (pregnant)</td>
<td>ZIKV</td>
<td>ZIKV DENV-1 DENV-2 DENV-3 DENV-4 WNV</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 0.6 &lt;30 &lt;30 &lt;30 &lt;30 &lt;30 &lt;30 &lt;30 &lt;30 ND &lt;10 10&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7 3.7 1428 1567 6102 12448 4590 150 10 &lt;10 10&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>14 9.6 8844 8787 7553 12372 5780 300 10 &lt;10 10&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>28 9.1 6570 4167 3807 6050 3240 300 10 &lt;10 10&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>44 7.3 3200 3688 2057 4419 2345 300 10 &lt;10 10&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>75 4.8 3106 2765 1876 2438 1230 300 10 &lt;10 10&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>103 3.7 2789 2485 1654 1653 765 300 10 &lt;10 10&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>218 1.9 2086 354 289 368 326 300 10 &lt;10 10&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>322 1.1 1863 318 213 322 286 ND 10 &lt;10 10&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D-19 (27, F, Jamaica, family visit)</td>
<td>Originally from Jamaica; 2</td>
<td>Experienced (pregnant)</td>
<td>ZIKV</td>
<td>ZIKV DENV-1 DENV-2 DENV-3 DENV-4 WNV</td>
<td></td>
</tr>
<tr>
<td></td>
<td>11 7.5 9676 8680 5272 8115 8170 600 10 &lt;10 10&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>26 6.5 8428 5438 4568 6985 6534 300 10 &lt;10 10&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>33 5.1 7069 4378 3482 5342 5428 300 10 &lt;10 10&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>52 3.4 3546 3685 2896 3564 4512 200 10 &lt;10 10&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>80 2.4 1864 3262 2786 2860 2874 &lt;10 &lt;10 &lt;10 &lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>172 2.1 962 658 754 1086 869 ND 10 &lt;10 10&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>301 0.9 847 527 436 964 548 ND 10 &lt;10 10&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E-18 (26, F, multiple Caribbean islands, vacation)</td>
<td>YF-17D vaccine in 2007; past history of extended travel in tropics; 8</td>
<td>Experienced (not pregnant)</td>
<td>ZIKV</td>
<td>ZIKV DENV-1 DENV-2 DENV-3 DENV-4 WNV</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8 4.2 778 &lt;30 &lt;30 &lt;30 &lt;30 &lt;30 &lt;30 ND &lt;10 10&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>38 7.8 4146 55 88 176 156 &lt;10 &lt;10 &lt;10 &lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>35 5.8 1118 50 &lt;30 101 129 &lt;10 &lt;10 &lt;10 &lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>347 1.2 743 &lt;30 &lt;30 &lt;30 &lt;30 &lt;30 &lt;30 ND &lt;10 10&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: Ab, antibody; DENV, dengue virus; DPO, days post onset of symptoms; FRNT_{50} titer, 50% focus reduction neutralization test titer; Ig, immunoglobulin; MAC-ELISA, IgM antibody-capture enzyme-linked immunosorbent assay; NA, not applicable; ND, not done; PCR, polymerase chain reaction; WNV, west nile virus; ZIKV, Zika virus.

* IgM testing was conducted using MAC-ELISA. ELISA values were patient serum optical densities divided by healthy control serum optical densities; <2, negative; 2–3 equivocal; >3 positive.

** IgG titers were determined as endpoint titers using indirect ELISA.

For pregnant patients C-16 and D-19, the DPOs corresponding to delivery are bolded.

patient; Figure 3A). Interestingly, memory B cells (MBCs) with cross-reactivity against DENV-1–4 developed (Figure 3B). Activated CD4+ T cells peaked moderately on DPO 9, but CD8+ T cells had a robust and prolonged plateau of activation (up to 26% of total blood CD8+ T cells) before decreasing toward a baseline on DPO 60 (Figure 1F–1G), the first time point when whole blood ZIKV RNA was negative (Figure 1B). Cytokine-producing antiviral CD4+ and CD8+ T cells against ZIKV C, prM, E, and NS5 peptides were demonstrated in ICS assays; first detected on DPO 9 and persisting through DPO 60 (Figure 4, Supplementary Table S1). Also, 41% of the antiviral CD4+ T cells were polyfunctional, that is, expressed ≥2 cytokines (Figure 4E).

Patient B-17. Five days after returning from Honduras, a 26-year-old nonpregnant flavivirus-naive woman developed typical Zika symptoms (Tables 1 and 2). ZIKV RNA was present in multiple body fluids (including whole blood through DPO 81, saliva, urine, and vaginal fluid; not shown, previously reported [22]). DENV and chikungunya RNA were not detected in plasma. On DPO 7, proinflammatory monocytes, mDCs, ASCs, and activated T cells were similar to those in patient A-23 (Figure 1C–1G; reported here for the first time). Anti-ZIKV IgM was positive and FRNT_{50} titer against ZIKV was 1438 on DPO 7; there were no NAbS against DENV nor binding Ab against WNV (Table 1, Figure 2A–2B; partially reported previously [22]). ZIKV-specific ASCs were identified using ELISpot, but no DENV-specific ASCs were present in this naive patient (Figure 3A). Cytokine-secreting E-specific CD4+ effector T cells, but not CD8+ T cells, were present (Supplementary Table S1).

Acute Zika—Human Immune Responses • CID 2018:66 (1 January) • 3
Table 2. Clinical Signs and Symptoms of 5 Patients with Acute Zika Infection

<table>
<thead>
<tr>
<th>Patient</th>
<th>Month and Year of Zika Infection</th>
<th>Days Post Onset of Symptoms at Enrollment</th>
<th>Rash (days)</th>
<th>Fever (days)</th>
<th>Conjunctivitis (days)</th>
<th>Joint Pain and/or Swelling (days)</th>
<th>Headache (days)</th>
<th>Eye Pain (days)</th>
<th>Myalgia (days)</th>
<th>Fatigue or Weakness (days)</th>
<th>Nausea or Diarrhea (days)</th>
<th>Cognitive Difficulty (days)</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>A-23</td>
<td>August 2016</td>
<td>5a</td>
<td>5</td>
<td>9</td>
<td>0</td>
<td>9</td>
<td>8</td>
<td>9</td>
<td>30</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B-17</td>
<td>May 2016</td>
<td>7</td>
<td>7</td>
<td>6</td>
<td>15</td>
<td>0</td>
<td>18</td>
<td>17</td>
<td>18</td>
<td>17, nausea</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-16</td>
<td>May 2016</td>
<td>3</td>
<td>4</td>
<td>4</td>
<td>0</td>
<td>28</td>
<td>103</td>
<td>2</td>
<td>103</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D-19</td>
<td>June 2016</td>
<td>11</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>52</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>E-18</td>
<td>May 2016</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>6</td>
<td>9</td>
<td>9</td>
<td>6</td>
<td>94</td>
<td>0</td>
<td>2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*On days post onset of symptoms 3 (in hospital emergency room preenrollment) patient A-23 had a low white blood cell count of 1900 cells/μL (normal, 4200–9100 cells/μL), with reduced absolute lymphocytes (550 cells/μL; normal, 720–3290 cells/μL), elevated reactive lymphocytes (20 cells/μL; normal, 0, an indication of viral infection), and low eosinophils (20 cells/μL; normal, 50–290 cells/μL). He also had elevated creatinine (1.21 mg/dL; normal, 0.7–1.2 mg/dL). These laboratory abnormalities resolved gradually over several days.

As we reported previously [22].

**Patient C-16.** A 36-year-old flavivirus-experienced missionary in Honduras was 9 weeks pregnant when she developed Zika (Table 1). Arthralgia persisted for 1 month; headache and fatigue were present through DPO 103, but she attributed fatigue to the pregnancy (Table 2). Plasma ZIKV RNA was positive from DPO 3 through 44 and became negative on DPO 75 (Figure 1A); plasma was negative for DENV and chikungunya RNA. Urine PCRs were positive for ZIKV RNA on DPOs 3 and 7 but not after that (Figure 1B). At delivery (DPO 218) ZIKV PCR of amniotic fluid and cord blood were negative, as was viral culture of the placenta. The newborn appeared healthy and remained so through age 4 months.

Cell phenotyping again revealed a transient increase in proinflammatory monocytes (Figure 1C) and a decrease in mDCs (Figure 1D). Anti-ZIKV IgM was initially negative (DPO 3), high equivocal on DPO 7, then positive through DPO 103, and negative at DPO 218 (delivery; Table 1). On DPO 3, DENV-specific NAb was detected in serum (Figure 2A and 2B, Table 1), but anti-ZIKV NAb was not detected until DPO 7 and then peaked on DPO 14 as plasma ZIKV RNA levels began to decrease. ZIKV- and DENV-specific NAb were long-lived; for example, on DPO 332 FRNT50 titers were 1863 and 322 [DENV-3], respectively. Phenotypic ASCs had a robust DPO 7 peak (22% of all blood B cells; Figure 1E). Like NAb, DENV-specific IgG-producing ASCs were first detected on DPO 3 using ELISpot and later (DPO 7) ZIKV-specific ASCs were detected (Figure 3A). As expected, MBCs against both ZIKV and all DENV serotypes were detected; anti-ZIKV MBCs underwent less decay (Figure 3B).

Moderate CD4+ T-cell activation (Figure 1F) and functional antigen-specific CD4+ T cells against C, prM, E, and NS5 peptides were present (Figure 4A and 4D). Strong CD8+ T-cell activation (27% of total blood CD8+ T cells) was detected early (DPO 3; Figure 1G) and persisted in association with prolonged plasma viral RNA (Figure 1A). However, functional (cytokine-producing) CD8+ T cells were either not detected (against C, prM, and E peptides) or present at only very low levels (NS5) in ICS assays performed repeatedly through DPO 75 (Figure 4B and 4D; Supplementary Table S1). Further phenotyping of the activated but apparently hypofunctional CD8+ T-cell subset identified markers of antigen-driven proliferation, tissue homing, and cytotoxic effector functions, indicating activation via the T-cell receptor (TCR) and not bystander activation (Supplementary Figure S3).

**Patient D-19.** A 27-year-old flavivirus-experienced, healthy, and pregnant US resident traveled to Jamaica to visit a relative. Soon after returning to the United States she developed acute Zika during the sixteenth week of gestation (Tables 1 and 2). Headache persisted for 52 days but had begun prior to her Zika illness. ZIKV RNA was present in plasma on DPOs 11 and 26 and not detected on DPO 33 (Figure 1A). qRT-PCR was negative for DENV and chikungunya RNA in plasma, ZIKV RNA in urine, and ZIKV RNA in amniotic fluid (DPO 33). The newborn appeared healthy and had remained so through 6 months.

Because her first study visit occurred later (DPO 11), monocyte, mDC, and ASC phenotyping did not identify the acute changes observed in other patients (Figure 1C–1E). Her anti-ZIKV IgM was positive through DPO 33; equivocal on DPOs 52, 80, and 172 through delivery; and negative on DPO 301 (Figure 2A, Table 1). High FRNT50 titers against both ZIKV and DENV were present.
on DPO 11 (eg, 9876 against ZIKV) and persisted (Figure 2A–2B, Table 1). Antigen-specific ASC ELISpot on DPO 11 was negative (missed peak; Figure 3A). MBCs against both ZIKV and DENV were present on DPOs 33, 80, and 301 (Figure 3B).

CD4+ T-cell activation was not observed (later initial time-point [DPO 11]; Figure 1F), but CD8+ T cells were activated and remained so through DPO 33 when plasma viral RNA became negative (Figure 1G). Antiviral cytokine-producing CD4+ T cells were detected by ICS; however, in this pregnant patient with prolonged viral RNA in plasma, functional CD8+ T cells against C, prM, E, and NS5 peptides were not detected (Figure 4, Supplementary Table S1).

Patient E-18. A 28-year-old nonpregnant woman developed acute Zika upon return to the United States from the Caribbean; she previously received YFV-17D vaccine and she also had a past history of extended travel in the tropics (Tables 1 and 2). On DPO 8 ZIKV RNA was detected in urine but not plasma; then negative in both from DPO 18 onward (Figure 1A-B). Phenotyping of monocyte, mDC, ASC, and activated T-cell populations demonstrated increases and decreases as for the other patients (Figure 1C–1G). IgM was positive on DPOs 8 through 35 and negative on DPO 347 (Figure 2A, Table 1). Nab titers against ZIKV were high and against DENV were low (Figure 2A–B, Table 1). ELISpot assays for ASC and MBC identified ZIKV- and DENV-specific cells (Figure 3). She produced functional effector T cells against ZIKV C, prM, E, and/or NS5 peptides at moderate (CD4+ subset) or low (CD8+ subset) levels (Figure 4, Supplementary Table S1).
DISCUSSION

Observations that characterize human immune responses to natural Zika infection are of importance for multiple groups that develop and test ZIKV vaccines in clinical trials. With a sample size of 5 it would be foolish to draw definitive or broad conclusions. However, in summarizing the data, a few interesting points for consideration emerge.

ZIKV RNA was detected in plasma from 4/5 patients and in urine from 3/4 patients tested. In 2 patients for whom whole blood was tested, viral RNA persisted longer in blood than in plasma or urine. Prolonged ZIKV RNA detection in patient A-23’s whole blood is consistent with previous reports of flavivirus persistence in whole blood (and viral association with red blood cells) for ZIKV [22, 25] and WNV [26, 27]. Whole blood may therefore provide a wider window for molecular diagnosis of Zika in upcoming vaccine efficacy studies.

DENV and chikungunya RNA were not detected in 3/3 patients tested, excluding coinfections. Despite persistent viral RNA in plasma, 2/2 pregnant women mounted robust phenotypic innate, T-, and B-cell responses; antigen-specific CD4+ T-cell responses; and NAb titers that were similar to those in nonpregnant patients. Both newborns were healthy. Neither pregnant woman had detectable functional CD8+ T-cell responses against ZIKV structural protein peptides (1 had a weak NS5 response). Their prolonged plasma ZIKV RNA was presumably due to shedding from infected placenta [28].
Early (DPO 3–9) transient increases in proinflammatory monocytes and slightly later (DPO 5–18) transient decreases in mDCs occurred. No clear patterns were observed for other monocyte subsets, plasmacytoid DC (pDC) or natural killer cells (NK). Knowledge of these cellular shifts during acute Zika infection may lead to pathways to exploit for vaccine or therapeutic development. Increases in blood CD14+CD16+ intermediate monocytes were also seen in acute dengue patients with high viral loads, and this population of cells was shown in vitro to mediate plasmablast differentiation and antibody production via B-cell activating factor (BAFF)/a proliferation-inducing ligand (APRIL) and interleukin (IL)-10. A decrease in blood mDCs was described for DENV infections where DCs are a major site for viral replication with resulting apoptosis [19, 29]. ZIKV, like many flaviviruses, infects human DCs [30, 31]. ZIKV antagonizes DC interferon responses in vitro [31].

Strong activation of CD8+ T cells (15% to >25% of blood CD8+ T cells) developed early and persisted in parallel with viral RNA. Moderate activation of CD4+ T cells (2%–5%) occurred. Lower, similar, and higher levels of T-cell activation were reported for YFV-17D, DENV, and Ebola acute infections, respectively [20, 32, 33].

Four patients studied before DPO 10 had robust phenotypic ASC responses (up to 31% of blood B cells). In flavivirus-experienced patients, ASCs against both ZIKV and DENV were present; in flavivirus-naive patients, only ZIKV-specific ASCs developed. This same pattern was seen for NAb. In experienced patients, ASC and NAb to DENV appeared earlier than those to ZIKV, emphasizing that NAb assays alone cannot be used.
for ZIKV diagnosis in flavivirus-experienced patients. Titers of ZIKV- and/or DENV-specific neutralizing Ab had impressive longevity (eg, DPO 332, patient C-16, titer 1863), as has been reported for other flaviviruses [34, 35]. ZIKV-specific MBCs were higher in flavivirus-naive patients—perhaps due to freedom from original antigenic sin. The development of MBC cross-reactive to DENV following Zika in a DENV-naive patient (eg, patient A-23) raises a theoretical possibility of antibody-dependent enhancement in a subsequent (first) DENV infection for such patients or for ZIKV vaccine recipients. Larger studies are needed to further address these observations.
In addition to 2 case reports we published recently [9, 36], we were unable to identify publications on ICS assays during human Zika infections. C-, prM-, E-, and NS5-specific cytokine-expressing CD4+ T cells developed in all patients tested, and 22%–46% of the responding cells were polyfunctional (Figure 4E). The generally absent or low detection of functional CD8+ effector T cells against peptides spanning ZIKV C, prM, E, and NS5 in this study is of interest. Further studies in larger samples and with peptides that span all 10 ZIKV proteins are needed. The high frequencies of activated CD8+ T cells compared to the absent or low magnitude of functional ZIKV-specific CD8+ effector T cells (eg, activated-to-functional ratio of 41:1 in patient A-23) was striking. In persistent viral infections (eg, human immunodeficiency virus, hepatitis C virus, lymphocytic choriomeningitis virus) and cancer, chronic antigen exposure causes CD8+ T-cell exhaustion (dysfunction) [37, 38]. In our study, the highly activated CD8+ T cells carried markers of exposure to antigen via TCR, which argued against bystander activation, yet few CD8+ T cells specific for the tested peptides were found.

In one study of dengue patients, the vast majority of proliferating, highly differentiated effector CD8+ T cells had acquired TCR refractoriness with deficient cytokine production. Transcriptomics revealed downregulation of TCR signaling molecules [32], leading the authors to infer that acute dengue’s massive CD8+ T-cell activation leads to downregulation of TCR signaling, producing a stunned phenotype previously described for other viruses [37, 38]. Also, with other flaviviruses, the structural proteins are predominantly targeted by CD4+ more than CD8+ T cells [39, 40]. The limited ZIKV-specific CD8+ T-cell response in pregnancy observed here deserves further study.

Finally, the public health significance of ZIKV RNA persistence in body fluids needs to be confirmed with culture or molecular assays that quantify replication-competent virus (a gap in the ZIKV clinical literature). Such efforts are underway in our laboratory. The clinical, viral, and immunologic findings in this small series of Zika patients may be of particular interest to clinicians and scientists planning vaccine studies.

Supplementary Data

Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Acknowledgements. The authors thank the study volunteers for their generous participation. For helpful scientific discussions we thank Toby Merlin, Walla Dempsey, Robert Johnson, Jens Wrammert, Mehul Suthar, and Rafi Ahmed. Thanks to Jesse Waggoner for performing semen PCR. We appreciate the contributions of the Georgia Department of Public Health; and the clinical contributions of Lara Harik, John P Horton, and Martina Badell from the Emory University Departments of Pathology, Obstetrics and Gynecology, and Maternal Fetal Medicine.

The Emory Zika Patient Study Team includes the byline coauthors and the following individuals: Briyana Domjahn, MPH, Dongli Wang, BS, Mary Bower, RN, Rijalda Deovic, BS, See Aramgum, BS, Sara Jo Johnson, BS, Dean Kleinhenz, BS, JoAnn Sadowski, BS, Talib Sirajud-Deen, BA (from Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Decatur, Georgia), and Jesse Waggoner, MD (from Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Decatur, Georgia and Emory TravelWell Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia).

Financial support. This work was supported by the Emory University School of Medicine; Emory Vaccine Center; Georgia Research Alliance; and the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Division of Microbiology and Infectious Diseases (DMID; contract HHSN272201300018I) and by a supplemental award to NIH/NIAID/DMID (grant AI115651).

Potential conflicts of interest. H. W. has received grant support from Takeda Vaccines, outside the submitted work. All other authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References